Blarcamesine for managing early Alzheimer’s disease in people aged 55 to 85 years

Blarcamesine is in clinical development for the treatment of mild cognitive impairment or earlystage mild dementia due to Alzheimer’s disease. Alzheimer’s disease is the most common cause of dementia in the UK. Alzheimer’s disease is a progressive condition, which means the symptoms develop gradually over many years and eventually become more severe. It affects multiple brain functions. Dementia is the name for a group of symptoms associated with an ongoing decline of brain functioning. It can affect memory, thinking skills and other mental abilities. The exact cause of Alzheimer’s disease is not yet fully understood, although several factors are thought to increase your risk of developing the condition. These include increasing age and family history. There’s currently no cure for Alzheimer’s disease, but medicines are available that can help relieve some of the symptoms.